Eli Lilly and Co banner

Eli Lilly and Co
F:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
F:LLY
Watchlist
Price: 861 EUR -2.14% Market Closed
Market Cap: €818.3B

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is hidden EUR. Compared to the current market price of 861 EUR, Eli Lilly and Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
F:LLY
973.8B EUR 14.9 47.2 31.8 33.8
US
Johnson & Johnson
NYSE:JNJ
575.5B USD 6.1 21.5 14.9 18.3
CH
Roche Holding AG
SIX:ROG
278.8B CHF 4.6 29.8 12.6 14.7
CH
Novartis AG
SIX:NOVN
231.7B CHF 5.3 21.3 13.2 16.9
UK
AstraZeneca PLC
LSE:AZN
219.5B GBP 5.2 32.4 15.4 22.6
US
Merck & Co Inc
NYSE:MRK
292.2B USD 4.5 16 10 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 10 11.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
157.5B USD 2.5 20.3 7.5 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
123.8B USD 2.6 17.5 6.9 8.8
UK
GSK plc
XETRA:GS71
101.8B EUR 2.7 15.4 7.8 11.1
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
F:LLY
Average P/E: 23.5
47.2
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
29.8
29%
1
CH
Novartis AG
SIX:NOVN
21.3
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.4
38%
0.9
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.3
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
UK
GSK plc
XETRA:GS71
15.4
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
F:LLY
Average EV/EBITDA: 42.1
31.8
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
CH
Novartis AG
SIX:NOVN
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.4
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10
7%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-13%
N/A
UK
GSK plc
XETRA:GS71
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
F:LLY
Average EV/EBIT: 90.5
33.8
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.4
CH
Novartis AG
SIX:NOVN
16.9
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.6
23%
1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-6%
N/A
UK
GSK plc
XETRA:GS71
11.1
12%
0.9